Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
93.11
-0.43 (-0.46%)
Delayed Quote
Updated: 11:08 AM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Mirum (MIRM) Q3 2026 Earnings Call Transcript
↗
November 04, 2026
Strong sales lift guidance as Mirum eyes cash-flow positive status.
Via
The Motley Fool
Topics
Earnings
Mirum Pharmaceuticals Q3 Earnings Call Highlights
↗
November 03, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued...
Via
MarketBeat
Topics
Earnings
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
November 03, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026
November 02, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat
↗
August 05, 2026
Via
Chartmill
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
October 27, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
October 26, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
October 21, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 15, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
↗
October 12, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic...
Via
MarketBeat
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
October 12, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
October 11, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
↗
October 02, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational...
Via
MarketBeat
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
September 28, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
September 27, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
September 25, 2026
From
Mirum Pharmaceuticals, Inc. and Incyte
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
September 08, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
September 02, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M.
Via
The Motley Fool
Topics
Earnings
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Q2 Earnings Call Highlights
↗
August 05, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining...
Via
MarketBeat
Topics
Earnings
Wondering what's happening in today's after-hours session?
↗
August 05, 2026
Via
Chartmill
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 05, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
July 29, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 13, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
June 14, 2026
From
Mirum Pharmaceuticals, Inc. and Incyte
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 04, 2026
From
Mirum Pharmaceuticals, Inc. and Incyte
Via
Business Wire
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
May 30, 2026
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
